{"id":23193,"date":"2024-08-12T09:28:34","date_gmt":"2024-08-12T13:28:34","guid":{"rendered":"https:\/\/medicarereport.org\/?p=23193"},"modified":"2024-08-12T09:28:35","modified_gmt":"2024-08-12T13:28:35","slug":"fda-gives-thumbs-down-to-mdma-for-now-demanding-further-research","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=23193","title":{"rendered":"FDA gives thumbs down to MDMA for now, demanding further research"},"content":{"rendered":"\n<p>(By Will Stone for NPR)<\/p>\n\n\n\n<p>On Friday, drugmaker Lykos Therapeutics received word from the Food and Drug Administration that the agency has decided not to approve MDMA-assisted therapy for PTSD at this time. Instead, the agency asked the drugmaker to further study the safety and efficacy of the treatment.  Continue reading <a href=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2024\/08\/09\/nx-s1-5068634\/mdma-therapy-fda-decision-ptsd-psychedelic-treatment\" data-type=\"link\" data-id=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2024\/08\/09\/nx-s1-5068634\/mdma-therapy-fda-decision-ptsd-psychedelic-treatment\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"54\" class=\"wp-image-3902\" style=\"width: 150px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Will Stone for NPR) On Friday, drugmaker Lykos Therapeutics received word from the Food and Drug Administration that the<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,15,494],"tags":[76,1457,180],"class_list":["post-23193","post","type-post","status-publish","format-standard","hentry","category-fda","category-part-dprescription-drugs","category-ptsd","tag-fda","tag-mdma","tag-ptsd"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23193"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23193\/revisions"}],"predecessor-version":[{"id":23194,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23193\/revisions\/23194"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}